{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:05:03Z","timestamp":1791057903905,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA157429"],"award-info":[{"award-number":["R01 CA157429"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA177558"],"award-info":[{"award-number":["P30 CA177558"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA264652"],"award-info":[{"award-number":["R01 CA264652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA272483"],"award-info":[{"award-number":["R01 CA272483"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266579"],"award-info":[{"award-number":["R01CA266579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA256893"],"award-info":[{"award-number":["R01 CA256893"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA256893"],"award-info":[{"award-number":["R01 CA256893"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007472","name":"University of Kentucky","doi-asserted-by":"publisher","award":["SCR_026358"],"award-info":[{"award-number":["SCR_026358"]}],"id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jbc.2025.108458","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T22:22:21Z","timestamp":1743200541000},"page":"108458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Artesunate enhances the efficacy of enzalutamide in advanced prostate cancer"],"prefix":"10.1016","volume":"301","author":[{"given":"Xinyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongsi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally R.","family":"Ellingson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiou","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2025.108458_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.jbc.2025.108458_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jbc.2025.108458_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jbc.2025.108458_bib4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jbc.2025.108458_bib5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial","volume":"376","author":"Dondorp","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jbc.2025.108458_bib6","first-page":"5995","article-title":"Anticancer activity of artemisinin and its derivatives","volume":"37","author":"Slezakova","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbc.2025.108458_bib7","first-page":"767","article-title":"The anti-malarial artesunate is also active against cancer","volume":"18","author":"Efferth","year":"2001","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jbc.2025.108458_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/diagnostics11030395","article-title":"Preclinical evaluation of artesunate as an antineoplastic agent in ovarian cancer treatment","volume":"11","author":"McDowell","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.jbc.2025.108458_bib9","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3390\/cancers13081885","article-title":"KEAP1 is required for artesunate anticancer activity in non-small-cell lung cancer","volume":"13","author":"Hill","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jbc.2025.108458_bib10","first-page":"1","article-title":"Targeting oncogenic myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2025.108458_bib11","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1101\/gad.1712408","article-title":"Myc\u2019s broad reach","volume":"22","author":"Eilers","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.jbc.2025.108458_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014407","article-title":"MYC and the control of apoptosis","volume":"4","author":"McMahon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jbc.2025.108458_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrc2819","article-title":"MYC as a regulator of ribosome biogenesis and protein synthesis","volume":"10","author":"van Riggelen","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbc.2025.108458_bib14","first-page":"1","article-title":"Alternative approaches to target myc for cancer treatment","volume":"6","author":"Wang","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.jbc.2025.108458_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbc.2025.108458_bib16","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbc.2025.108458_bib17","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/pros.23437","article-title":"The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: implications for prostate cancer Health disparities research using pre-clinical models","volume":"77","author":"Woods-Burnham","year":"2017","journal-title":"The Prostate"},{"key":"10.1016\/j.jbc.2025.108458_bib18","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1074\/jbc.RA119.011385","article-title":"Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance","volume":"295","author":"Li","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbc.2025.108458_bib19","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202103090","article-title":"The long journey to bring a Myc inhibitor to the clinic","volume":"220","author":"Whitfield","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jbc.2025.108458_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/1477-3163.83937","article-title":"Androgen receptor signaling in prostate cancer development and progression","volume":"10","author":"Lonergan","year":"2011","journal-title":"J. Carcinog."},{"key":"10.1016\/j.jbc.2025.108458_bib21","first-page":"189","article-title":"Molecular mechanisms of enzalutamide resistance in prostate cancer","volume":"2","author":"Blatt","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.jbc.2025.108458_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","article-title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2025.108458_bib23","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.2147\/OTT.S153764","article-title":"Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions","volume":"11","author":"Tucci","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.jbc.2025.108458_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.canlet.2010.01.013","article-title":"Overexpression of c-myc induces epithelial mesenchymal transition in mammary epithelial cells","volume":"293","author":"Cho","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbc.2025.108458_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fendo.2018.00129","article-title":"The role for myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues","volume":"9","author":"Goetzman","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.jbc.2025.108458_bib26","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/pros.24602","article-title":"Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer","volume":"83","author":"Zhang","year":"2023","journal-title":"The Prostate"},{"key":"10.1016\/j.jbc.2025.108458_bib27","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2025.108458_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41467-024-44686-5","article-title":"Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC","volume":"15","author":"Panja","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2025.108458_bib29","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbc.2025.108458_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3635","article-title":"A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression","volume":"8","author":"Holmes","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbc.2025.108458_bib31","first-page":"875","article-title":"Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer","volume":"7","author":"Semenas","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jbc.2025.108458_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk5382","article-title":"Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction","volume":"384","author":"Liu","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jbc.2025.108458_bib33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40264-018-0667-x","article-title":"Safety experience during real-world use of injectable artesunate in public Health facilities in Ghana and Uganda: outcomes of a modified cohort event monitoring study (CEMISA)","volume":"41","author":"Ampadu","year":"2018","journal-title":"Drug Saf."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825003072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925825003072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:27:55Z","timestamp":1748467675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925825003072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0021925825003072"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2025.108458","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artesunate enhances the efficacy of enzalutamide in advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2025.108458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology\u00e9","name":"copyright","label":"Copyright"}],"article-number":"108458"}}